Investigational drug · Phase 2
BTZ-043
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Tuberculosis.
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
8
Any phase or sponsor naming "BTZ-043"
First trial start
2022
Jul 26, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BTZ-043", any sponsor or status.
Conditions studied
As listed on its trial records.
- Tuberculosis
Approved drugs for the same conditions: Tuberculosis · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "BTZ-043" as an intervention, largest first.
- Platform Assessing Regimens and Durations In a Global Multisite Consortium for TBPivotal-lookingRecruiting
University College, LondonAcademic, hospital or other
NCT06114628 · 2,500 participants (planned) · Start Jan 9, 2024 · Primary completion Feb 24, 2027
Drug: Ganfeborole; BTZ-043 and 11 more · For: Pulmonary Tuberculosis
Sites: Chisinau, Moldova; Cape Town, South Africa; George, South Africa · 11 sites in all
- PanACEA - STEP2C -01Pivotal-lookingRecruiting
Michael HoelscherAcademic, hospital or other
NCT05807399 · 390 participants (planned) · Start Apr 14, 2023 · Primary completion Oct 31, 2027
Drug: BTZ-043; Rifampicin and 9 more · For: Pulmonary Tuberculosis; Other Specified Pulmonary Tuberculosis
Sites: Lambaréné, Gabon; Blantyre, Malawi; Maputo, Mozambique · 10 sites in all
- Study of Combinations of Novel Promising Drugs for Pulmonary TuberculosisPivotal-lookingNot yet recruiting
TASK Applied ScienceAcademic, hospital or other
NCT07773610 · 135 participants (planned) · Start Sep 25, 2026 · Primary completion Dec 30, 2027
Drug: TBAJ-587 50 mg; Pretomanid 200mg and 5 more · For: Tuberculosis, Pulmonary
Sites: Cape Town, South Africa
GlaxoSmithKlineGSK (GSK)
NCT05382312 · 127 participants · Start Jul 26, 2022 · Primary completion May 27, 2025
Drug: GSK3036656; Bedaquiline and 6 more · For: Tuberculosis
Sites: Bellville, South Africa
Michael HoelscherAcademic, hospital or other
NCT05926466 · 92 participants · Start Sep 21, 2023 · Primary completion Dec 27, 2024
Drug: BTZ-043; Bedaquiline and 2 more · For: Tuberculosis, Pulmonary; Other Specified Pulmonary Tuberculosis
Sites: Cape Town, South Africa; George, South Africa; Mbeya, Tanzania · 4 sites in all
Michael HoelscherAcademic, hospital or other
NCT04044001 · 78 participants · Start Nov 15, 2019 · Primary completion Mar 3, 2022
Drug: BTZ-043; Rifafour e-275® and 2 more · For: Pulmonary Tuberculoses; Other Specified Pulmonary Tuberculosis
Sites: Cape Town, South Africa · 2 sites in all
Michael HoelscherAcademic, hospital or other
NCT03590600 · 30 participants · Start Jun 7, 2018 · Primary completion Aug 14, 2018
Drug: BTZ-043; Placebo · For: Tuberculosis; Tuberculosis, Pulmonary; Bacterial Infections and 2 more
Sites: Neu-Ulm, Germany
Michael HoelscherAcademic, hospital or other
NCT04874948 · 4 participants · Start Oct 8, 2021 · Primary completion Oct 15, 2021
Drug: 500mg BTZ-043 containing 3.7 MBq of [14C]BTZ-043 · For: Tuberculosis; Tuberculosis, Pulmonary; Bacterial Infections Respiratory and 2 more
Sites: Groningen, Netherlands
Newest research
PubMed records naming it or its code names, newest first.
- Assessing Multiple Treatment Regimens for Tuberculosis.
Esmail H, Paton NI, Schildkraut JA, et al. · N Engl J Med 2026
- Hydride-Meisenheimer metabolism in mammals - scope of an overlooked biotransformation pathway.
Joch M, Bernal FA, Torres-Gómez H, et al. · Bioorg Chem 2026
- Modeling Treatment Response in Tuberculosis Early Bactericidal Activity Trials.
McClean MCW, Koele SE, Dreisbach J, et al. · CPT Pharmacometrics Syst Pharmacol 2026
- An evaluation of designs for Phase I/IIa dose-finding studies in Tuberculosis.
Serra A, Mozgunov P, Phillips PP, et al. · Stat Methods Med Res 2026
- HIV-associated drug-resistant TB: expanded treatment options and emerging threats.
Abadie M, Kay A · Curr Opin HIV AIDS 2026
- Low-level BTZ-043 resistance in Mycobacterium tuberculosis and cross-resistance to bedaquiline and clofazimine.
Ghodousi A, Iannucci I, Saluzzo F, et al. · IJTLD Open 2025
Also in development for Tuberculosis
- BCGPhase 38 trials
ImmunityBio, Inc. · Non-muscle Invasive Bladder Cancer (NMIBC), Papillary-Only Non-muscle-invasive Bladder Cancer, Tuberculosis
- MTBVACBBV169Phase 32 trials
Biofabri, S.L · Tuberculosis, Tuberculosis (TB)
- TB-PPDPurified Protein Derivative of TuberculinPhase 32 trials
Chengdu CoenBiotech Co., Ltd · Tuberculosis, Latent Tuberculosis Infection
- DelamanidPhase 22 trials
WestVac Biopharma Co., Ltd. · Tuberculosis, Multidrug Resistant Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis
- BNT164a1Phase 21 trial
BioNTech SE · Tuberculosis
- BNT164b1Phase 21 trial
BioNTech SE · Tuberculosis
- GSK3036656Phase 21 trial
GSK · Tuberculosis
- JDB0131Phase 21 trial
WestVac Biopharma Co., Ltd. · Tuberculosis, Multidrug Resistant Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from GSK.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.